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T akotsubo cardiomyopathy (TC) is characterised by acute, transient left ventricular apical ballooning precipitated by emotional or physiologically stressful stimuli and has been previously associated with Grave’s disease based on a few clinical reports. More recently, the association with exogenous thyrotoxicosis and radioiodine-induced thyroiditis has also been described. Iatrogenic 
hyperthyroidism on patients on levothyroxine replacement therapy for hypothyroidism has not been reported as a cause of TC. The authors 
describe two female patients with TC associated with levothyroxine over-replacement. A 74-year-old and a 48-year-old female patient, 
medicated with levothyroxine (respectively, 2.27 μg/kg and 1.85 μg/kg) for autoimmune thyroiditis were admitted to our emergency room 
with precordial pain. The first had an electrocardiogram with ST-segment elevation in the anterior precordial leads, and the latter had sinus 
tachycardia with deep T-wave inversion and QT interval prolongation. Further investigation revealed a mild elevation of cardiac biomarker 
levels and severe apical hypokinesis, but no significant coronary lesions on catheterisation. The suppressed thyroid stimulating hormone 
(TSH) levels were verified in the cardiac intensive care unit: 0.21 and 0.07 mIU/l (0.35–5.50) respectively. Both patients showed improvement 
of the apical hypokinesis on the discharge echocardiogram and normalisation of cardiac biomarker levels. Levothyroxine dose was reduced. 
This case report focuses on the cardiovascular risks of thyrotoxicosis, emphasises the importance of correct dose adjustment on patients 
under levothyroxine replacement therapy and stresses that TSH should be determined in patients presenting with acute coronary syndrome 
and typical findings of TC.
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Takotsubo cardiomyopathy (TC), frequently referred as stress-induced cardiopathy, apical 
ballooning syndrome or ‘broken heart’ syndrome, is characterised by left ventricular ballooning 
and transient systolic dysfunction. The Japanese term ‘takotsubo’ means a trap to catch an 
octopus, and its shape resembles this condition’s left ventricular systolic appearance.1
Clinically, TC can mimic an acute coronary syndrome (precordial pain, ST segment elevation 
or T-wave inversion in the electrocardiographic anterior precordial leads, elevation of cardiac 
biomarkers), but the segmental motility changes happen in the absence of coronary obstruction.2 
TC is frequently associated with the occurrence of a stressful event, physical or emotional, however, 
the pathogenic mechanism is not fully understood. There is growing evidence of occurrence of TC 
in patients with thyrotoxicosis, pointing out that this may be a potential precipitating factor.3
Classically, TC has been mostly classified according to its ventricular involvement (uni- or 
biventricular), ballooning pattern (apical, basal, mid-ventricular and localised) and typical or atypical 
presentation.4,5 A new classification has been proposed regarding potential triggers, stating that 
secondary forms of TC (including patients with thyrotoxicosis) are associated with a worse long-
term prognosis compared with primary forms.6 
Case report
Case 1
A 74-year-old female patient with history of auto-immune thyroiditis, dyslipidemia and rheumatoid 
arthritis, medicated with levothyroxine (2.27 μg/kg), calcium carbonate and cholecalciferol 
1,250 mg plus 400 IU id, simvastatin 20 mg id, escitalopram 10 mg id and macrogol 10,000 mg id. 
She presented in the emergency room with chest pain with sensation of tightness, nausea and 
vomiting, occurring after physical effort and lasting for six hours. She reported increased anxiety 
levels and fatigue during the past two weeks, but denied other significant clinical complaints such 
as weight loss, tremor, anxiety, sweating, increased appetite or increased bowel movements.
The electrocardiogram (ECG) showed ST-segment elevation in the anterior precordial leads (see 
Figure 1) and in the echocardiogram there was significant hypokinesis of the anterior and inferior 
portions of the apex with left ventricular systolic dysfunction (left ventricular ejection fraction [LVEF] 
43%). Blood tests showed a rise of cardiac biomarkers: troponin value of 7.43 ng/ml (0.00–0.07). 
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Cardiac catheterisation (see Figure 2) was performed and no evidence of 
coronary disease was found.
The suppression of TSH was detected in the cardiac intensive care unit: 0.21 
mIU/l (0.35–5.50), with a free T4 of 1.43 ng/dl (0.80–1.80). Levothyroxine 
dose was then reduced. The patient showed great recovery, with rapid 
decrease of cardiac biomarkers and good clinical outcome. She was 
asymptomatic on discharge. The echocardiographic re-evaluation after 
three months showed complete reversion of apical hypokinesis.
Case 2
A 47-year-old female patient with history of auto-immune thyroiditis, 
hypertension, dyslipidemia and non-Hodgkin lymphoma in complete 
remission, medicated with levothyroxine (1.85 μg/kg), acetylsalicylic 
acid 100 mg id, telmisartan/hydrochlorothiazide 40/12.5 mg id and 
pitavastatin 2 mg id.
She was admitted to the emergency room with palpitations and chest 
pain radiating to her left arm that started after emotional stress. She 
mentioned that she was experiencing effort-related retrosternal 
discomfort lately. She did not refer to other prior clinical complaints. The 
ECG showed sinus tachycardia (144 bpm), symmetrical T-wave inversion 
in the left ventricular leads, associated with prolonged QT interval (see 
Figure 1). The subsequent complementary workup showed a discrete 
rise in cardiac biomarkers (troponin levels of 0.28 ng/ml, 0.00–0.07) and 
apical hypokinesis without significant coronary obstruction on coronary 
angiography. She also had a TSH level inferior to the lower limit of the 
reference range: 0.07 mIU/l (0.35–5.50). 
Similarly to what was previously described, her levothyroxine dose was 
adjusted and there was normalisation of cardiac biomarkers during 
inpatient care (troponin level of 0.09 ng/ml, 0.00–0.07 on the fourth day 
after admission).
Cardiac magnetic resonance was performed three weeks after discharge, 
it did not show any signs of late myocardial enhancement and already 
showed improvement of the morphological abnormalities previously 
described. Her echocardiographic re-evaluation after three months 
showed normal left ventricular contractile function.
Comment
Many clinical manifestations of thyrotoxicosis are due to thyroid 
hormone action on the myocardial tissue, peripheral circulation and 
sympathetic nervous system, leading to a hyperdynamic state. Thyroid 
hormones contribute, directly and indirectly, to an increase of myocardial 
contractility and heart rate, thus increasing cardiac output, myocardial 
oxygen consumption, systolic blood pressure and pulmonary pressure, 
while there is a decrease in peripheral vascular resistance and in diastolic 
pressure.7 The main cardiovascular complications of thyrotoxicosis 
are atrial fibrillation, heart failure and pulmonary hypertension.8 
Thyrotoxicosis is also associated with an increased risk of angina and 
even acute coronary syndrome, which is thought to be explained by the 
increase of myocardial oxygen demand caused by thyroid hormones, 
potentiating the occurrence of ischaemic events.9 Therefore, it is 
important to include TSH evaluation in the initial assessment of patients 
with those conditions.
Figure 1: Electrocardiogram – patient 1 on admission (A) 
and two days following (B), showing T-wave invertion; 
patient 2 on admission (C)
Figure 2: Cardiac catheterisation of the first patient, with a 
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Several reports support the association between TC and thyrotoxicosis. 
Although the mechanism is not fully understood, it is generally considered 
to involve an abnormal myocardial response to the circulating levels 
of catecholamines.10 The fact that there is an increased sensibility to 
catecholamines in thyrotoxicosis would justify its potential association 
with TC. This increased sensibility may entail an over-expression of G 
protein, down-regulation of the catalytic subunit of cardiac-specific 
adenylyl cyclase or an increased density of beta-adrenergic receptors. 
These receptors are found more densely spaced in the ventricular apex, 
which substantiates this segment’s vulnerability to hypokinesis in TC.11
There is no specific treatment for TC. This condition is managed with 
supportive therapy and usually results in rapid resolution of symptoms 
and reversion of the left ventricular dysfunction.12 It is recommended 
to solve potential underlying factors, when those can be identified: 
emotional or physical stress reduction and, as in the present cases, 
approach to thyrotoxicosis. 
Both our patients presented with precordial pain, there was no strong 
clinical suspicion of pheochromocytoma or cerebrovascular disease and 
coronary artery disease was excluded. TC diagnosis was established 
in both and on the first case no drug or other precipitating factor was 
found other than excessive supplementation with levothyroxine, despite 
subclinical levels. The second patient referred to emotional stress, adding 
to the excessive supplementation with levothyroxine.
These case reports alert for the cardiovascular risks of sustained 
thyrotoxicosis, stressing the relevance of adequate dose-adjustment and 
regular clinical monitoring of patients on thyroid hormone replacement 
therapy, especially those with other cardiovascular risk factors. 
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